Tan Li
Founder bei SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
Vermögen: 471 Mio $ am 31.03.2024
Profil
Tan Li gründete die Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Frau Li ist Executive Director & Deputy General Manager bei diesem Unternehmen und Executive Partner bei Urumqi Jintiantu Equity Investment Partnership LP. Frau Li ist auch im Vorstand von Kymab Ltd, Shenzhen Techdow Pharmaceutical Co., Ltd, Shenzhen Duopule Industrial Development Co., Ltd. und Kymab Group Ltd. Sie erhielt einen Bachelor-Abschluss von der Sichuan University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.06.2023 | 408 041 280 ( 32,72% ) | 471 Mio $ | 31.03.2024 |
Aktive Positionen von Tan Li
| Unternehmen | Position | Beginn |
|---|---|---|
| SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. | Founder | 21.04.1998 |
| Urumqi Jintiantu Equity Investment Partnership LP | Corporate Officer/Principal | 09.08.2013 |
| Shenzhen Techdow Pharmaceutical Co., Ltd. | Director/Board Member | - |
Shenzhen Duopule Industrial Development Co., Ltd.
 Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The private company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million. | Director/Board Member | 13.01.2014 |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Director/Board Member | 20.01.2017 |
Ausbildung von Tan Li
| Sichuan University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
| Urumqi Jintiantu Equity Investment Partnership LP | |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| Shenzhen Techdow Pharmaceutical Co., Ltd. | |
Shenzhen Duopule Industrial Development Co., Ltd.
Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The private company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million. | Distribution Services |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Health Technology |
